TB‑500 (a synthetic peptide fragment of thymosin beta‑4) has been studied primarily in animal models, where it appears to influence wound healing, inflammation modulation, and muscle regeneration. Human data are sparse and consist mainly of uncontrolled case reports.
Safety data in humans are limited. Potential concerns include immune reactions, vascular effects, and unknown long‑term consequences. Lack of robust clinical trials makes risk assessment uncertain.
TB‑500 is not approved by major health agencies (e.g., FDA, EMA) for therapeutic use. It is generally marketed as a research chemical, and distribution for human consumption may be prohibited.
This page is intended solely for educational purposes.